Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
The company’s lead program, MB272, targets the immune receptor B- and T-lymphocyte attenuator and advance pipeline of checkpoint agonist antibodies designed to treat autoimmune disease.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The proprietary technology is covered by patents describing the application and use of RPI-78M in the treatment of autoimmune diseases, including Multiple Sclerosis (MS).
Lead Product(s): RPI-78M
Therapeutic Area: Immunology Product Name: RPI-78M
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
AstraZeneca will be responsible for all future research, development and commercialization of the STING inhibitor compounds, and F-star will retain rights to all STING agonists, currently in clinical development for patients with cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $312.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement July 08, 2021
Details:
Proceeds from the investment will support advancement of Apollo's robust pipeline into development, expansion of the company's operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $145.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 17, 2021
Details:
C4XD’s small molecule IL-17A inhibitor programme can selectively block IL-17 activity in vivo while maintaining the molecular size of the molecule in the traditional “drug-like” range suitable for oral administration.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $505.5 million Upfront Cash: $8.5 million
Deal Type: Licensing Agreement April 12, 2021
Details:
The United States Patent and Trademark Office has now formally approved its patent application (US Patent Application no. 16/351,620), in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.
Lead Product(s): SDC-1802
Therapeutic Area: Immunology Product Name: SDC-1802
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options.
Lead Product(s): SDC-1802
Therapeutic Area: Immunology Product Name: SDC-1802
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
